Michele Stanchina

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐<scp>GemOx</scp>: A Multicenter Cohort Study

American Journal of Hematology 2025cited by 10position: middledoi

<scp>PET</scp>/<scp>CT</scp> in the Staging and Treatment Response Assessment of Patients With Extranodal Marginal Zone Lymphoma

American Journal of Hematology 2025cited by 6position: middledoi

289 | MULTICENTER REAL‐WORLD OUTCOMES OF FRONTLINE POLA‐R‐CHP IN TREATMENT NAÏVE DLBCL

Hematological Oncology 2025cited by 2position: middledoi

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia

Nature Reviews Clinical Oncology 2024cited by 21position: firstdoi

Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial

The Lancet Haematology 2024cited by 21position: middledoi

Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma

Clinical Lymphoma Myeloma & Leukemia 2024cited by 3position: middledoi

The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions

Frontiers in Oncology 2023cited by 54position: middledoi

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date

Cancer Management and Research 2022cited by 12position: middledoi

Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development

Cancers 2020cited by 70position: firstdoi

No grants ingested yet.

Recent publications